SUMMARY The effects on ventricular arrhythmia of acebutolol were compared with those of propranolol in 31 patients who averaged more than 30 ventricular premature complexes (VPCs) per hour during 72 hours of ambulatory ECG recording during a placebo-controlled baseline period. The study consisted of an initial 2-week placebo-controlled baseline period followed by two 6-week double-blind treatment periods consisting of incremental dose-titration, maintenance and dose-tapering schedules. The treatment during the double-blind period was randomized to either oral acebutolol or propranolol given three times daily. Acebutolol is a new cardioselective A-blocking agent'4 that possesses mild intrinsic sympathomimetic activity,15' 16 which differs from propranolol, the most widely used and well-studied noncardioselective and nonagonist f-adrenergic blocking agent. In the present study, we compared the effectiveness of acebutolol and propranolol in reducing the frequency and complexity of spontaneous and exercise-related VPCs in a large group of patients with chronic (nonsustained) ventricular arrhythmia using a placebocontrolled, double-blind, randomized crossover study design.
MANY f-ADRENERGIC blocking agents with different ancillary properties studied in well-controlled clinical trials have been shown to reduce the frequency of ventricular premature complexes (VPCs), especially those augmented by exercise. 17 However, the comparative efficacy of such agents has not been investigated. The interest in identifying A-blocking agents with minimal adverse effects on bronchial8 S and vascular smooth muscle'0' 11 (so-called cardioselective agents) and limited adverse effects on glucose metabolism12' 19 further suggests the need for such comparative studies to identify effective and safe antiarrhythmic drugs for chronic treatment of VPCs.
Acebutolol is a new cardioselective A-blocking agent'4 that possesses mild intrinsic sympathomimetic activity,15' 16 which differs from propranolol, the most widely used and well-studied noncardioselective and nonagonist f-adrenergic blocking agent. In the present study, we compared the effectiveness of acebutolol and propranolol in reducing the frequency and complexity of spontaneous and exercise-related VPCs in a large group of patients with chronic (nonsustained) ventricular arrhythmia using a placebocontrolled, double-blind, randomized crossover study design.
Methods

Subjects
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(32%) lacked evidence of structural heart disease and systemic lupus erythmatosus were excluded from six had other cardiac diagnoses (table 1) A laboratory profile, including a complete blood count, erythrocyte sedimentation rate, platelet count, urinalysis, blood sugar, BUN, creatinine, SGOT, SGPT, bilirubin, alkaline phosphatase, LDH, uric acid, serum sodium, potassium, calcium and fluorescent antinuclear antibody titer, was obtained before entry and at the end of each double-blind treatment period.
Twenty-four-hour ambulatory ECGs were performed on three sequential days (72 hours) during the initial single-blind placebo period and on the final day of each dose-titration and maintenance phase and drug-free week ( fig. 1 ). Each ambulatory recording was analyzed by Cardio Data System (Haddonfield) as reported previously.'7 The hourly VPC frequency was analyzed and classified.
VPCs were classified according to a modification of the grading system of Lown and Wolf'8: 1 = fewer than 30 VPCs/hour; 2 = 30 or more VPCs/hour; 3 = multiform VPCs; 4 = couplets; and 5 = ventricular tachycardia (three or more repetitive VPCs). Earlycycle VPCs (R-on-T) were not included in this analysis because the significance of this criterion in ambulatory patients is controversial. '9 Treadmill exercise tests were done at the end of the placebo period and on the final day of the maintenance phases to evaluate occurrence of exercise-induced arrhythmia.20 Each exercise test consisted of identical, sequential 3-minute stages of increasing work load (speed and percent elevation) on a calibrated, motordriven treadmill according to a modification of the Bruce protocol.2' The patients performed maximally symptom-limited exercise in the presence of one of the investigators. Exercise tests were analyzed for the heart rate, systolic and diastolic blood pressure, calculated rate-pressure product at peak exercise, total exercise time and the reason for exercise limitation.
VPC frequency and complexity (highest grade) during exercise were evaluated by visual inspection and quantitation of all beats from a compressed singlechannel ECG recording that included the upright exercise time and 10 minutes of supine rest after exercise. The VPC frequency and classification recorded during each exercise test were verified independently by at least two of the investigators.
Statistical Analysis
Statistical methods used included the paired t test and the Wilcoxon rank-sum test as used by Winkle et al. 22 Intraindividual-hour and 24-hour VPC counts, log (total VPCs + 1.01), and highly hourly VPC classification were compared for the initial placebo, second placebo, acebutolol and propranolol treatments. Group mean data were similarly analyzed AMB-ECrIII During the initial 24 hours of placebo treatment, the heart rate averaged 81 i 10 beats/min (± SD), the average frequency of VPCs from the 24-hour ambulatory recording was 477 ± 418 VPCs/hour (range VPCs/hour), and ventricular tachycardia (nonsustained) was recorded in 15 patients. The second and third sequential 24-hour ECG recordings during placebo treatment revealed similar mean heart rates, VPC frequencies and grades for this group and only modest intraindividual spontaneous fluctuations (tables 1 and 2). Individual fluctuations in VPC frequency were modest for the group as estimated by the comparison of the standard deviation of the mean hourly VPC rate with the magnitude of the mean hourly VPC rate during each day of the 3 days of placebo treatment. The ratio of the standard deviation of the mean to the mean hourly VPC frequency was less than 30% ( fig. 2) .
Similarly, comparison of the VPC rate for each patient during the second and third day of placebo treatment with the first day showed that most patients had Abbreviations: VPC = ventricular premature complex; DT = dose titration; maint. = maintenance.
(16% reduction). Acebutolol significantly reduced the mean VPC frequency and grade for the group recorded on the final day of the dose-titration and maintenance periods compared with the'initial placebo period (table 1, fig. 4) . Similarly, the number of patients with ventricular tachycardia, paired VPCs and multiform VPCs was reduced during acebutolol treatment (table 3) . No significant differences in the dose-titration and maintenance periods were observed for mean VPC frequency or grade or the number of patients with specific complex VPC forms during acebutolol treatment.
Propranolol, mean dose 202 ± 63 mg/day, produced a heart rate of 67 ± 7 beats/min (18% reduction compared with the initial placebo period). Propranolol significantly reduced the mean VPC fre- quency and grade for the group recorded on the final day of the dose-titration and maintenance periods compared with the initial placebo period (table 1, fig.  4 ). Similarly, the number of patients with ventricular tachycardia, paired VPCs and multiform VPCs was reduced during propranolol treatment compared with placebo treatment (table 3) . No significant differences in the dose-titration and maintenance periods were observed for VPC frequency or grade or the number of patients with specific complex VPC forms during propranolol treatment (tables 1, 2 and 3). Acebutolol and propranolol treatments were not statistically differen't with respect to the mean heart rate, mean VPC frequerncy or grade and number of patients with complex VPC forms.
Treadmill Exercise Tests During Placebo, Acebutolol and Propranolol Treatment
The values for resting and peak exercise heart rates, systolic blood pressure and rate-pressure product were significantly reduced by both acebutolol and propranolol compared with the initial placebo-controlled baseline period (table 4) , thereby confirming comparable ,B-adrenergic blocking activity for both drugs. The total exercise time du'ring placebo was 438 ± 174 seconds and changed insignificantly after acebutolol (486 ± 162 seconds) and propranolol (444 ± 192 seconds) treatments (table 3) . Statistical analyses showed no significant differences in heart rate, systolic blood pressure, rate-pressure product, total exercise time or work between acebutolol and propranolol.
With placebo treatment the number of VPCs during exercise testing averaged 160 ± 202 (range 0-880 VPCs) and was reduced significantly by both acebutolol and propranolol ( Shand34 and Vaughn-Williams37 suggested that the antiarrhythmic effects of ,B blockers (especially propranolol) are closely related to the production of ,B blockade because at the doses used in man, direct effects (variously referred to as nonspecific, local anesthetic, quinidine-like or membrane-stabilizing effects) are not seen.34 8" However, this concept is controversial. Woosley et al.' suggested that antiarrhythmic effects are dissociated from the f-adrenergic effects of propranolol.
Beta blockers can vary with respect to factors that alter their clinical value.'2' 16, 31 Pharmacologic properties, including cardioselectivity, partial agonist activity and other differences, make comparative studies of different agents a necessity.'0' 12, 16, 31 Acebutolol has clinical electrophysiologic properties similar to those of propranolol.38 39 Acute highdose acebutolol in man has produced His-Purkinje delays, as measured by the HV interval, when plasma levels exceeded 1000 ng/ml.38 This effect has not been observed for propranolol, which has been suggested as safe for patients with abnormalities of the specialized conduction system.39 This pharmacologic activity may play an important role in suppressing ventricular arrhythmias. Each of the type 1 antiarrhythmic agents prolongs His-Purkinje conduction, a property that may be valuable in treating reentrant ventricular arrhythmia.
The lack of a progressive dose-dependent bradycardia with agents possessing partial agonist activity has been reported in patients with angina pectoris,21 40 and suggests that differential properties among (-adrenergic blockers are relevant clinically.
Exercise-related Ventricular Arrhythmia
Quantitation of exercise-related ventricular arrhythmia during treadmill exercise is a new and unstandardized tool for evaluating the efficacy of different antiarrhythmic treatments.20 24 36, 41 It also lacks the sensitivity of ambulatory ECG recordings for detecting important ventricular arrhythmia.7' 24, 42 However, the exercise method of provoking arrhythmia may reveal unique information with regard to electrophysiologic mechanisms,20 24 33, 36 examines an activity that is common for most patients, augments potentially dangerous increases in adrenergic activity, and is widely available. Therefore, we assessed the effects of acebutolol and propranolol, compared with placebo, on the frequency and complexity of exerciserelated as well as spontaneous ventricular arrhythmia. Both A-blocking agents were equally effective in reducing the frequency and grade of exercise-related VPCs.
